StockViz
Share URL
Embed chart view
-
Export .csv
-
Download image
-
Copy link
-
Embed code
StockViz
RANKINGS
Cipla Limited
NSE:CIPLA.NS
Sector
Location
Market Cap
USD 14.12 B
Share Price
USD 17.33
Avg Daily Volume
1,583,273
Change (1 day)
0.44%
Change (1 year)
-4.49%
Change (YTD)
-2.97%
Cipla Limited EBIT Margin for the year ending March 31, 2025: 22.18%
Cipla Limited EBIT Margin is 22.18% for the year ending March 31, 2025, a -2.36% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
-
Cipla Limited EBIT Margin for the year ending March 31, 2024 was 22.72%, a 23.48% change year over year.
-
Cipla Limited EBIT Margin for the year ending March 31, 2023 was 18.40%, a 10.49% change year over year.
-
Cipla Limited EBIT Margin for the year ending March 31, 2022 was 16.65%, a -7.98% change year over year.
-
Cipla Limited EBIT Margin for the year ending March 31, 2021 was 18.09%, a 27.58% change year over year.
Competitors
Eli Lilly and Company
USD 771.75
LLY
-27.59
-3.45%
AbbVie Inc.
USD 186.39
ABBV
-5.13
-2.68%
Roche Holding AG
USD 337.03
RO.SW
-6.82
-1.98%
AstraZeneca PLC
USD 140.43
AZN.L
-2.72
-1.90%
Merck & Co., Inc.
USD 81.52
MRK
-2.15
-2.57%
Amgen Inc.
USD 292.51
AMGN
-4.52
-1.52%
Pfizer Inc.
USD 24.61
PFE
-0.74
-2.92%
Gilead Sciences, Inc.
USD 109.06
GILD
-3.03
-2.70%
Sanofi
USD 95.94
SAN.PA
-1.50
-1.54%
Bristol-Myers Squibb Company
USD 46.43
BMY
-0.91
-1.92%
GSK plc
USD 18.76
GSK.L
-0.36
-1.89%
Chugai Pharmaceutical Co., Ltd.
USD 45.53
4519.T
-0.47
-1.02%
Regeneron Pharmaceuticals, Inc.
USD 547.96
REGN
-22.63
-3.97%
Cencora, Inc.
USD 294.65
COR
-2.41
-0.81%
Jiangsu Hengrui Medicine Co., Ltd.
USD 8.01
600276.SS
+0.03
0.41%
Takeda Pharmaceutical Company Limited
USD 29.48
4502.T
-0.38
-1.26%
Haleon plc
USD 4.86
HLN.L
-0.07
-1.38%
Daiichi Sankyo Company, Limited
USD 23.31
4568.T
+0.41
1.79%
Ucb S.A.
USD 198.03
UCB.BR
-3.24
-1.61%
BeOne Medicines Ltd.
USD 269.70
ONC
+17.56
6.96%
Key Data
| Date | EBIT Margin | EBITDA Margin | Net Income Margin | EBT Margin |
|---|
Competitors
Eli Lilly and Company
USD 771.75
LLY
-27.59
-3.45%
AbbVie Inc.
USD 186.39
ABBV
-5.13
-2.68%
Roche Holding AG
USD 337.03
RO.SW
-6.82
-1.98%
AstraZeneca PLC
USD 140.43
AZN.L
-2.72
-1.90%
Merck & Co., Inc.
USD 81.52
MRK
-2.15
-2.57%
Amgen Inc.
USD 292.51
AMGN
-4.52
-1.52%
Pfizer Inc.
USD 24.61
PFE
-0.74
-2.92%
Gilead Sciences, Inc.
USD 109.06
GILD
-3.03
-2.70%
Sanofi
USD 95.94
SAN.PA
-1.50
-1.54%
Bristol-Myers Squibb Company
USD 46.43
BMY
-0.91
-1.92%
GSK plc
USD 18.76
GSK.L
-0.36
-1.89%
Chugai Pharmaceutical Co., Ltd.
USD 45.53
4519.T
-0.47
-1.02%
Regeneron Pharmaceuticals, Inc.
USD 547.96
REGN
-22.63
-3.97%
Cencora, Inc.
USD 294.65
COR
-2.41
-0.81%
Jiangsu Hengrui Medicine Co., Ltd.
USD 8.01
600276.SS
+0.03
0.41%
Takeda Pharmaceutical Company Limited
USD 29.48
4502.T
-0.38
-1.26%
Haleon plc
USD 4.86
HLN.L
-0.07
-1.38%
Daiichi Sankyo Company, Limited
USD 23.31
4568.T
+0.41
1.79%
Ucb S.A.
USD 198.03
UCB.BR
-3.24
-1.61%
BeOne Medicines Ltd.
USD 269.70
ONC
+17.56
6.96%